The Impact Of CKD And T2D Is Far-reaching

29 million Americans have T2D

374 million people have T2D worldwide. And that number is growing1

CKD patients are 10x more likely to die of CVD than ESKD

Patients with stage 3 CKD are 10x more likely to die from any cause (including CVD) than to progress to dialysis or kidney transplantation2,3*

ESKD is 10x more prevalent in T2D patients

Prevalence of end-stage kidney disease (ESKD) is 10 times higher in patients with diabetes compared to those without4

CKD shortens life by 16 years

CKD can shorten life expectancy of T2D patients by up to 16 years, relative to the general population5

CKD: chronic kidney disease; CVD: cardiovascular disease; ESKD: end-stage kidney disease; T2D: type 2 diabetes.

*A Norwegian 10-year observational study of all patients with CKD stage 3 and diabetes mellitus (N=3047).3
In pooled data of diabetes mellitus patients from 54 countries.4

For 40% of T2D patients, the development of CKD may be the result of damage initiated by T2D.6

Increased risk of cardiovascular (CV) events appears early in the course of CKD and grows with time.7-9


This can lead to organ failure and death. While it is possible for patients with CKD and T2D to die from T2D alone, even higher mortality due to CV events and ESKD is a reality.6,7,10


    CKD increases the CV burden for patients with T2D12

    Patients with CKD in T2D have a higher comorbidity of CV disease


    An evaluation of patients in Germany with CKD in T2D compared to T2D patients without CKD (N=343,675)

    10-year mortality increases with an impaired GFR and presence of albuminuria10

    eGFR increases 10 year mortality chart

    A survey examining the all-cause mortality of patients with T2D in the US, with or without CKD (N=15,046).


    Urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) are recommended annual tests for determining kidney function and damage.13


    CKD progression in T2D relentlessly follows the path toward declining kidney function, CV decline, and ultimately ESKD. Once renal function declines below a certain threshold, patients face the complications and risks associated with ESKD.7

    The standard treatments (transplant or dialysis) are far from optimal14:

    • Dialysis has a significant patient burden and a mortality rate of up to 20% per year
    • Transplantation is limited by organ shortages

    Once patients reach ESKD, approximately 60% will die in the next 5 years. Even the finest dialysis care or transplant results will at best achieve much less than a naturally functioning kidney, which is why protecting the kidney from CKD progression is of primary importance.2,7

    ESKD rates have remained flat, despite advancements in treatment for T2D7,15

    Treatment hasn’t changed ESKD rates chart

    Since the 1990s, advancements in glucose and blood pressure control have made important gains in reducing T2D complications. This is especially true in regards to CV events. Yet despite these gains, patients with CKD and T2D still face a substantive risk of CKD progression.7,15 

    The incidence of ESKD in particular has improved the least, indicating that there may be a unmet need in the current standard of care.15

    Learn more about the drivers of CKD progression
    Learn More
    Watch how inflammation and fibrosis are triggered by MR overactivation
    Watch Video

    How well do you know CKD in T2D?

    Take the Quiz


    MR: mineralocorticoid receptor.